Published in Gene Therapy Weekly, July 27th, 1998
The TelVysion probes utilize Vysis' Fluorescence In Situ Hybridization (FISH) technology to visually detect cryptic, difficult to identify translocations associated with cancer and other diseases.
Designed for research use only, Vysis' TelVysion probes were developed in connection with a research and exclusive license agreement with The University of Chicago, Illinois, which was announced in September 1997. Vysis' TelVysion DNA probes...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.